You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

List of Excipients in Branded Drug POTASSIUM CITRATE


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing POTASSIUM CITRATE

Excipient Strategy and Commercial Opportunities for Potassium Citrate

Last updated: February 27, 2026

What is Potassium Citrate’s Role as an Excipient?

Potassium citrate functions primarily as an active pharmaceutical ingredient (API) for its alkali and citrate properties, but it can also serve as an excipient in formulations. Its uses as an excipient include acting as a buffering agent, pH stabilizer, and alkalizing agent in oral and injectable medications. It influences the solubility and stability of drug products, particularly in formulations requiring pH adjustment.

How Does Potassium Citrate Fit into Pharmaceutical Formulation Strategies?

Buffering and pH Adjustment

Potassium citrate maintains optimal pH levels in formulations. Its use stabilizes drug stability and ensures consistent bioavailability. It is preferred in formulations sensitive to pH variations, such as in antacids, diuretics, and electrolyte replenishment products.

Solubility Enhancement

In drug delivery, potassium citrate enhances solubility of poorly soluble APIs through complexation or by adjusting pH. It is valuable in developing liquid and injectable forms, where solubility directly impacts bioavailability.

Formulation Compatibility

Potassium citrate's compatibility profile makes it suitable for combined drug products. It does not interact significantly with common excipients like cellulose derivatives, maltodextrin, or polyvinylpyrrolidone, allowing integration into various formulation types.

Market Dynamics and Commercial Opportunities

Market Size and Growth

The global pharmaceutical excipients market was valued at approximately USD 8.8 billion in 2022 and is projected to grow at a CAGR of around 6.3% from 2023 to 2030 (BIS Research, 2023). Potassium citrate, as part of the citrate and alkalizing excipients segment, benefits from the emerging focus on electrolyte balance therapies and pH stabilization.

Key Drivers

  • Rising prevalence of electrolyte disorders and chronic kidney disease increases demand for formulations utilizing potassium citrate.
  • Growth in generic drug development drives the demand for cost-effective excipients capable of improving drug stability.
  • Advancements in drug delivery systems, including liquid and injectable formulations, require effective pH and solubility agents such as potassium citrate.

Regulatory and Manufacturing Considerations

Potassium citrate is classified as a GRAS (Generally Recognized As Safe) additive, facilitating its regulatory approval. Its high solubility, stability, and availability from multiple suppliers support large-scale manufacturing and supply chain resilience.

Competitive Landscape and Supply Chain

Leading suppliers include FMC Corporation, Jungbunzlauer, and Roquette, offering pharmaceutical-grade potassium citrate. Market entry for new suppliers requires compliance with pharmacopeial standards (USP, EP, JP) and demonstrated purity (≥99%).

Innovation and Formulation Trends

  • Development of dual-function excipients combining pH buffering with controlled-release capabilities.
  • Incorporation into electrolyte replenishment formulations for sports and clinical hydration.
  • Use in compounded formulations targeting rare electrolyte imbalances.

Challenges and Considerations

  • Price fluctuations due to raw material input variability.
  • Limited patent protection, leading to commoditization.
  • Regulatory stringency in certain jurisdictions can delay market entry.

Strategic Recommendations

  • Invest in characterizing excipient performance in emerging formulations, such as high-concentration electrolyte solutions.
  • Build supply chain redundancy to mitigate raw material price volatility.
  • Pursue formulations that leverage potassium citrate’s compatibility and stabilizing effects to differentiate products.

Summary Table

Aspect Details
Market size (2022) USD 8.8 billion (excipients segment)
Growth rate (2023-2030) ~6.3% CAGR
Major suppliers FMC Corporation, Jungbunzlauer, Roquette
Regulatory status GRAS, included in USP, EP, JP pharmacopeias
Principal uses pH buffer, solubility enhancer, alkalizing agent

Key Takeaways

  • Potassium citrate’s excipient functions are vital in electrolyte, pH stabilization, and solubility enhancement.
  • Market growth is driven by electrolyte therapy needs and formulation innovations.
  • Supply chain resilience and regulatory compliance are critical for commercial success.
  • Innovation in dual-purpose excipients can create new value propositions.
  • Price volatility and commoditization challenge new market entrants.

FAQs

  1. Can potassium citrate be used as a multifunctional excipient?
    Yes. It functions as a buffering agent, alkalizing agent, and solubility enhancer, which simplifies formulation designs.

  2. What are the regulatory hurdles for excipient manufacturers?
    Compliance with pharmacopeial standards (USP, EP, JP) and demonstrating purity and stability are essential. Regulatory approvals are generally straightforward due to its GRAS status.

  3. What are the main applications of potassium citrate in pharmaceuticals?
    Treatments for electrolyte imbalances, formulations requiring pH control, and electrolyte replenishment products.

  4. How can companies differentiate their potassium citrate excipients?
    By achieving higher purity, improving particle size uniformity, and developing formulations with added functionalities like controlled-release.

  5. What emerging markets could increase demand for potassium citrate?
    Elderly care, chronic kidney disease management, sports hydration products, and novel electrolyte therapy formulations.


References

  1. BIS Research. (2023). Global Pharmaceutical Excipients Market Report.

  2. United States Pharmacopeia (USP). (2022). USP Dictionary of Standards.

  3. European Pharmacopoeia (EP). (2022). European Pharmacopoeia Monographs.

  4. Japanese Pharmacopoeia (JP). (2022). JP Pharmacopoeia Standards.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.